Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of diminazene as a dual inhibitor of SARS-CoV-2 human host proteases TMPRSS2 and furin using cell-based assays

1 Jan 2022

Abstract excerpt

The proteases TMPRSS2 (transmembrane protease serine 2) and furin are known to play important roles in viral infectivity including systematic COVID-19 infection through priming of the spike protein of SARS-CoV-2 and related viruses. To discover small-molecules capable of inhibiting these host proteases, we established convenient and cost-effective cell-based assays employing Vero cells overexpressing TMPRSS2 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Phagocytosis and Immune Regulation
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35815069
DOI: 10.1016/j.crchbi.2022.100023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of diminazene as a dual inhibitor of SARS-CoV-2 human host proteases TMPRSS2 and furin using cell-based assaysPMID 35815069Read ↗

The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 TreatmentSemantic proximity Read ↗

Structure, activity and inhibition of human TMPRSS2, a protease implicated in SARS-CoV-2 activationSemantic proximity Read ↗

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entrySemantic proximity Read ↗

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorSemantic proximity Read ↗

Dual inhibition of vacuolar ATPase and TMPRSS2 is required for complete blockade of SARS-CoV-2 entry into cellsSemantic proximity Read ↗

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host CellsSemantic proximity Read ↗

Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19Semantic proximity Read ↗

TMPRSS2: A Key Host Factor in SARS-CoV-2 Infection and Potential Therapeutic TargetSemantic proximity Read ↗

Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19Semantic proximity Read ↗

Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19Semantic proximity Read ↗

Impact of TMPRSS2 Expression, Mutation Prognostics, and Small Molecule (CD, AD, TQ, and TQFL12) Inhibition on Pan-Cancer Tumors and Susceptibility to SARS-CoV-2.Semantic proximity Read ↗

Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.